EMA accepts Rigel's marketing application for fostamatinib for immune thrombocytopenia; shares up 2% premarket [Seeking Alpha]
Rigel Pharmaceuticals, Inc. (RIGL)
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rigel.com
Company Research
Source: Seeking Alpha
EMA accepts Rigel's marketing application for fostamatinib for immune thrombocytopenia; shares up 2% premarketRigel Pharmaceuticals (NASDAQ:RIGL) is up2% premarket on light volume on the heels of itsannouncement that the European Medicines Agency (EMA) has accepted for review its marketing application seeking approval for fostamatinib for the treatment of adult patients with chronic immune thrombocytopenia (low blood platelets).An opinion from the advisory group CHMP should be announced by Q4 2019.Fostamatinib is currently available in the U.S. under the brand name TAVALISSE.See all stocks on the move »Now read:Omeros: Substantial Unlocked Value In The GPCR Franchise »Subscribefor full text news in your inbox
Show less
Read more
Impact Snapshot
Event Time:
RIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RIGL alerts
High impacting Rigel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RIGL
News
- Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy? [Yahoo! Finance]Yahoo! Finance
- Rigel to Present at the Piper Sandler 37th Annual Healthcare ConferencePR Newswire
- Rigel Pharmaceuticals: Behind The Huge Rally [Seeking Alpha]Seeking Alpha
- Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology [Yahoo! Finance]Yahoo! Finance
- Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & OncologyPR Newswire
RIGL
Earnings
- 11/4/25 - Beat
RIGL
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/4/25 - Form 8-K
- 11/4/25 - Form 10-Q
- RIGL's page on the SEC website